You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Boehringer Ingelheim
Express Scripts
Medtronic
Baxter

Last Updated: July 10, 2020

DrugPatentWatch Database Preview

Insulin glargine - Biologic Drug Details


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for insulin glargine

Identify potential brand extensions & biosimilar entrants

SponsorPhase
All India institute of medical sciences, RaipurPhase 4
Institute of Post-Graduate Medical Education and Research, KolkataPhase 4
Postgraduate Institute of Medical Education and ResearchPhase 4

See all insulin glargine clinical trials

Recent Litigation for insulin glargine

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc.2018-05-31
SANOFI-AVENTIS U.S. LLC v. MERCK SHARP & DOHME CORP.2017-08-08
Purdue Pharmaceutical v. Actavis Elizabeth LLC2015-05-13

See all insulin glargine litigation

Company Disclosures: US Patents for insulin glargine

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Sanofi Aventis Us LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081 001 2000-11-17   Start Trial Medimpex Ets. (Balzers, LI) 2012-02-21 RX company
Sanofi Aventis Us LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081 001 2000-11-17   Start Trial Medimpex Ets (LI) 2013-04-23 RX company
Sanofi Aventis Us LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081 001 2000-11-17   Start Trial Hoechst Aktiengesellschaft (Frankfurt am Main, DE) 2014-08-12 RX company
Sanofi-aventis U.s. Llc LANTUS insulin glargine INJECTION, SOLUTION 021081 1 2017-06-04   Start Trial Medimpex Ets. (Balzers, LI) 2012-02-21 company
Sanofi-aventis U.s. Llc LANTUS insulin glargine INJECTION, SOLUTION 021081 1 2017-06-04   Start Trial Medimpex Ets (LI) 2013-04-23 company
Sanofi-aventis U.s. Llc LANTUS insulin glargine INJECTION, SOLUTION 021081 1 2017-06-04   Start Trial Hoechst Aktiengesellschaft (Frankfurt am Main, DE) 2014-08-12 company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for insulin glargine

These patents were identified by searching patent claims

Supplementary Protection Certificates for insulin glargine

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
13/34 Ireland   Start Trial PRODUCT: INSULIN DEGLUDEC IN ALL ITS FORMS AS THEY ARE PROTECTED BY THE BASIC PATENTS; REGISTRATION NO/DATE: IRELAND EU/1/12/807-001, 004, 005, 007-009, 012, 013 AND 015 / 21/01/2013
00597 Netherlands   Start Trial PRODUCT NAME: INSULINE DEGLUDEC EN INSULINE ASPART; REGISTRATION NO/DATE: EU/1/12/806/001EU/1/12/806/004EU/1/12/806/005EU/1/12/806/007EU/1/12/806/008 2013210121
2013902170499 Italy   Start Trial PRODUCT NAME: INSULINA DEGLUDEC(TRESIBA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/12/807/001-4-5-7-8-9-12-13-15, 20130121
13/034 Ireland   Start Trial PRODUCT NAME: INSULIN DEGLUDEC; NAT REGISTRATION NO/DATE: EU/1/12/807-001, 004, 005, 007-009, 012, 013 015 20130121
0596 Netherlands   Start Trial PRODUCT NAME: INSULINE DEGLUDEC; NATIONAL REGISTRATION NO/DATE: EU/1/12/807/004 20130123; FIRST REGISTRATION: EU EU/1/12/807/001 20130123
90042 Netherlands   Start Trial PRODUCT NAME: INSULIN ASPART; REGISTRATION NO/DATE: EU/1/99/119/001 - EU/1/99/119/005 19990907
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Dow
Colorcon
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.